Industry-sponsored economic studies in critical and intensive care versus studies sponsored by nonprofit organizations

Journal of Intensive Care Medicine

Volumn 18, Issue 5, 2003, Pages 265-268

  Hartmann, Michael ^a   Knoth, Holger ^a   Schulz, Diane ^a   Knoth, Sven ^b   Meier Hellmann, Andreas ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b EUROPEAN UNIVERSITY VIADRINA   (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

Author keywords

Conflict of interest; Health economics; Sponsorship

Indexed keywords

ARTICLE; ASSISTIVE TECHNOLOGY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; ECONOMIC ASPECT; INTENSIVE CARE; MEDICAL RESEARCH; NON PROFIT ORGANIZATION; PRIORITY JOURNAL; PUBLICATION; QUALITATIVE ANALYSIS; SENSITIVITY ANALYSIS; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST CONTROL; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH SERVICES RESEARCH; HUMAN; INDUSTRY; INFORMATION PROCESSING; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PUBLISHING; QUALITATIVE RESEARCH; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

COST CONTROL; CRITICAL CARE; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; HEALTH SERVICES RESEARCH; HUMANS; INDUSTRY; INTENSIVE CARE; ORGANIZATIONS, NONPROFIT; PUBLISHING; QUALITATIVE RESEARCH; RESEARCH DESIGN; RESEARCH SUPPORT; SENSITIVITY AND SPECIFICITY; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 1842840920     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066603255683     Document Type: Article

References (13)

1. Morin K, Rakatansky H, Riddick F, et al. Managing conflicts of interest in the conduct of clinical trials. JAMA. 2002;287:78-84.
2. Montaner J, Shaughnessy M, Schechter M. Industry-sponsored clinical research: a double-edged sword. Lancet. 2001;358:1893-1895.
3. Smith R. Beyond conflict of interest: transparency is the key. Br Med J. 1998;317:291-292.
4. Krimsky S, Rothenberg LS. Financial interest and its disclosure in scientific publications. JAMA. 1998;280:225-226.
5. Stelfox HT, Chua G, O'Rourke K, Detsky A. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338:101-106.
6. Rochon PA, Gurwitz JU, Simms RW, et al. A study of manufacturer-supported trials of non-steroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994;154:157-163.
7. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med. 1986;1:155-158.
8. Barbieri M, Drummond M. Conflict of interest in industry-sponsored economic evaluations: real or imagined. Curr Oncol Rep. 2001;3:410-413.
9. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennet CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282:1453-1456.
10. Knox KS, Adams JR, Djulbegovic B, Stinson TJ, Tomor C, Bennet CL. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Ann Oncol. 2000;11:1513-1515.
11. Drummond MF, Jefferson TO, on behalf of the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J. 1996;313:275-283.
12. Callahan M, Wears R, Weber E, Barton C, Young G. Positive outcome bias and other limitations in the outcome research of research abstracts submitted to a scientific meeting. JAMA. 1998;280:254-257.
13. Oxford Centre for Evidence-Based Medicine. Levels of evidence and grades of recommendations. Retrieved December 20, 2002, from http://163.1.96.10/docs/ levels.html